Risk factor thresholds

BMJ

Volumn 325, Issue 7372, 2002, Pages 1114-

  Soljak, Michael A ^a   Kendrick, Malcolm E ^b   Laitner, Steven M ^c   Law, Malcolm ^d   Wald, Nicholas J ^d  

^a North West London Perinatal Network   (United Kingdom)

^b Adelphi Lifelong Learning   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT;

AGE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHESIS; ISCHEMIC HEART DISEASE; LETTER; OBESITY; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SMOKING; CORONARY ARTERY DISEASE; NOTE; PRACTICE GUIDELINE;

ANTILIPEMIC AGENTS; CORONARY DISEASE; GUIDELINES; HUMAN; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; HUMANS;

EID: 0037048961     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.325.7372.1114     Document Type: Letter

References (13)

1. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002; 324: 1570–1576. (29 June.)
2. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of CHD in clinical practice. Heart 1998; 80(suppl 2): S1–29.
3. Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU, Yeo WW, et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of CHD and cost of drug treatment. Heart 1999; 82: 325–332.
4. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002; 324: 1570–1576. (29 June.)
5. Law MR, Wald NJ. Why heart disease mortality is low in France: the time lag explanation [with commentaries by M Stampfer, E Rimm, D J P Barker, J P Mackenbach, and A E Kunst]. BMJ 1999; 318: 1471–1480.
6. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987; 257: 176–180.
7. Okayama A, Ueshima H, Marmot MG, Nakamura M, Kita Y, Yamakawa M. Changes in total serum cholesterol and other risk factors for cardiovascular disease in Japan 1980-1989. Int J Epidemiol 1993; 22: 1038–1047.
8. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001; 358: 351–355.
9. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002; 324: 1570–1576. (29 June.)
10. Beyth RJ, Shorr RI. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging 1999; 14: 231–239.
11. Malhotra S, Karan RS, Pandhi P, Jain S. Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance. Postgrad Med J 2001; 77: 703–707.
12. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
13. Law MR, Thompson SG, Wald NJ. Serum cholesterol reduction and health: assessing possible hazards. BMJ 1994; 308: 373–379.